Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02953704 · ClinicalTrials.gov registry record
Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
A clinical trial, sponsored by Incyte Corporation.
- Completed
- Registry status
- 1,469
- Enrollment target
NCT02953704: Completed study, sponsored by Incyte Corporation.
NCT02953704 is a clinical trial that has completed, run by Incyte Corporation. The registered enrollment target is 1,469 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02953704 has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- 1,469 participants
- Enrollment target
Study Summary
The purpose of this prospective, longitudinal, noninterventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofibrosis (MF).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,469 participants |
| Start Date | 2016-12-31 |
| Est. Completion | 2022-03-29 |
What the finished NCT02953704 record still lists
NCT02953704 is an observational study that tracks outcomes without assigning an intervention. Its 1,469 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02953704 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02953704 about?
NCT02953704 is a clinical study titled "Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)". The purpose of this prospective, longitudinal, noninterventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofibrosis (MF).
What is the current status of trial NCT02953704?
This trial is currently completed. The enrollment target is 1,469 participants. The study started on 2016-12-31. Estimated completion is 2022-03-29.
Who is sponsoring clinical trial NCT02953704?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT05869552 · 1,485 participants · NA
Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI